Damora Therapeutics, Inc. Common Stock (DMRA) Expected to Announce Quarterly Earnings on Wednesday

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) is projected to release its Q2 2026 resultson Wednesday, August 5th. Analysts expect Damora Therapeutics, Inc. Common Stock to post earnings of ($0.4470) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). On average, analysts expect Damora Therapeutics, Inc. Common Stock to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Damora Therapeutics, Inc. Common Stock Stock Performance

NASDAQ DMRA opened at $28.56 on Tuesday. Damora Therapeutics, Inc. Common Stock has a one year low of $2.45 and a one year high of $38.33. The stock has a 50-day moving average of $26.06 and a 200 day moving average of $26.12. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -5.12 and a beta of 1.47.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $76,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth approximately $49,000. Connective Capital Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the third quarter worth approximately $100,000. Geode Capital Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth approximately $266,000. Finally, Remedium Capital Partners LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth approximately $2,772,000. Institutional investors own 14.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on DMRA shares. Jefferies Financial Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They set a “buy” rating and a $50.00 price target on the stock. TD Cowen started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They set a “buy” rating for the company. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Finally, Wedbush raised their target price on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.